Q - Adaptive Biotechnologies

For the period ended Jun 30, 2025. Filed Aug 5, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 5, 2025

ADPT$30.26+8.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Revenue	$58,879	$43,190	$111,322	$85,063
Operating expenses
Cost of revenue	17,999	19,317	34,978	37,368
Research and development	24,134	25,353	48,337	55,598
Sales and marketing	23,573	20,314	46,620	42,633
General and administrative	17,786	17,895	35,185	37,492
Amortization of intangible assets	423	424	842	847
Impairment of long-lived assets	—	7,205	—	7,205
Total operating expenses	83,915	90,508	165,962	181,143
Loss from operations	(25,036)	(47,318)	(54,640)	(96,080)
Interest and other income, net	2,391	3,766	5,070	7,988
Interest expense	(2,948)	(2,696)	(5,853)	(5,689)
Net loss	(25,593)	(46,248)	(55,423)	(93,781)
Add: Net (income) loss attributable to noncontrolling interest	(21)	26	(43)	52
Net loss attributable to Adaptive Biotechnologies Corporation	$(25,614)	$(46,222)	$(55,466)	$(93,729)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	$(0.17)	$(0.31)	$(0.37)	$(0.64)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	152,082,284	147,414,095	150,646,632	146,600,811

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.